

# PRODUCT INFORMATION



## N-desmethyl Imatinib

Item No. 16947

**CAS Registry No.:** 404844-02-6  
**Formal Name:** N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-(1-piperazinylmethyl)-benzamide

**Synonyms:** N-desmethyl Gleevec,  
STI-509-00

**MF:** C<sub>28</sub>H<sub>29</sub>N<sub>7</sub>O  
**FW:** 479.6


**Purity:** ≥95%

**UV/Vis.:** λ<sub>max</sub>: 237, 270 nm

**Supplied as:** A lyophilized solid

**Storage:** -20°C

**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

N-desmethyl Imatinib is supplied as a lyophilized solid. A stock solution may be made by dissolving the N-desmethyl imatinib in the solvent of choice, which should be purged with an inert gas. N-desmethyl Imatinib is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of N-desmethyl imatinib in these solvents is approximately 0.2, 14, and 16 mg/ml, respectively.

N-desmethyl Imatinib is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, N-desmethyl imatinib should first be dissolved in DMF and then diluted with the aqueous buffer of choice. N-desmethyl Imatinib has a solubility of approximately 0.2 mg/ml in a 1:4 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

N-desmethyl Imatinib is a major active metabolite of imatinib (Item No. 13139), an anticancer agent that selectively targets tyrosine kinases, including Bcr-ABL, platelet-derived growth factor receptor (PDGFR), and KIT.<sup>1,2</sup> N-desmethyl Imatinib is formed when imatinib undergoes demethylation by the cytochrome P450 (CYP) isomer CYP3A4.<sup>3</sup> N-desmethyl Imatinib has the same *in vitro* potency at Bcr-ABL kinase as imatinib (IC<sub>50</sub> = 38 nM for both) but is only present in plasma at 10-15% of the levels of imatinib, indicating the majority of the anticancer activity can be attributed to the parent compound.

### References

1. Druker, B.J. Translation of the Philadelphia chromosome into therapy for CML. *Blood* **112**(13), 4808-4817 (2008).
2. Müller, B.A. Imatinib and its successors-how modern chemistry has changed drug development. *Cur. Pharm. Des.* **15**(2), 120-133 (2009).
3. Obach, R.S. Pharmacologically active drug metabolites: Impact on drug discovery and pharmacotherapy. *Pharmacol. Rev.* **65**(2), 578-640 (2013).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/06/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM